Yükleniyor... / Loading...
This study examined the effect of the drug Fostamatinib on skin inflammation (cutaneous inflammation) in patients with moderate to severe hidradenitis suppurativa. It enrolled patients diagnosed by a physician with moderate to severe (Hurley Stage 2 or 3) hidradenitis suppurativa. It was a Phase 2 study and is completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Moderate to Severe (Hurley Stage 2 or 3) Hidradenitis Suppurativa as determined by the PI Exclusion Criteria: * Uncontrolled hypertension (systolic blood pressure \[BP\] ≥135 mmHg and/or diastolic BP ≥85 mmHg), unstable angina, congestive heart failure of New York Heart Association classification III or IV, serious cardiac arrhythmia requiring treatment (exceptions: atrial fibrillation, paroxysmal supraventricular tachycardia) at screening. * History of myocardial infarction within 3 months prior to screening. * Shock or hypotension requiring vasoactive peptides, such as dopamine, norepinephrine, epinephrine, or dobutamine at screening or at randomization. * Renal function impairment with creatinine clearance \<30 mL/min at screening (estimated glomerular filtration rate will be calculated using the modification of diet in renal disease equation). * Liver function impairment with aspartate aminotransferase/alanine aminotransferase \>=3x the upper limit of normal or bilirubin \>2X the upper limit of normal at screening. * Neutrophil count \<1000/µL at screening. * History of an allergic reaction or hypersensitivity to the study treatment or any component of the study treatment formulation. * Has documented HIV infection or documented, active hepatitis B or hepatitis C infection. * Women lactating, pregnant or of childbearing potential who are not willing to avoid becoming pregnant during the study. * Individuals with concurrent use of systemic antibiotics/ oral retinoids/ systemic immunosuppressants (those with prior use of these medications must have conducted a washout period of 4 weeks or 5 half-lives of the drug, whichever is longer). * Any medical, psychological or social condition that, in the opinion of the Investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data.